---
title: "Datapharm expands SRD Search into France"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305684420.md"
description: "Datapharm has expanded its SRD Search service to France via VIDAL, following launches in the UK and Germany. Pfizer is the first manufacturer to provide Scientific Response Documents on the platform. The service aims to give healthcare professionals 24/7 access to trusted medical information while providing manufacturers with analytics on search habits. This expansion supports Datapharm's goal of increasing access to verified medicine data across Europe."
datetime: "2026-11-16T14:10:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305684420.md)
  - [en](https://longbridge.com/en/news/305684420.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305684420.md)
generator: "portal-rs"
---

# Datapharm expands SRD Search into France

Datapharm has launched its SRD Search functionality on VIDAL in France, marking the third market for the service following its introduction on emc in the UK and Rote Liste in Germany.

Pfizer is the first pharmaceutical company to make its Scientific Response Documents (SRDs) available to French healthcare professionals through the platform. Since the service went live in August 2026, Pfizer has published 373 French-language SRDs covering nine brands.

According to Datapharm, 14 pharmaceutical companies now use SRD Search across the UK, Germany and France, with adoption continuing to increase.

The company said search data from the UK and Germany has revealed distinct differences in healthcare professional behaviour. In Germany, nine out of 10 searches contain a single word, while more than half are conducted in English rather than German.

A significant proportion of searches in both countries also takes place outside the operating hours of traditional Medical Information services.

The launch on VIDAL is expected to generate similar insights into the information needs and search habits of French healthcare professionals. Participating manufacturers will receive analytics reports detailing search activity, timing and unanswered questions, enabling them to refine content for the French market.

Rob Morgan, Chief Executive Officer of Datapharm, said: “Healthcare professionals need answers they can trust, yet increasingly the first answer they see comes from a tool that cannot distinguish a verified response from an invented one.

“Manufacturers have already done the hard work of writing and reviewing these documents. SRD Search puts that trusted content where French HCPs already look, at any hour.”

He added: “Launching on VIDAL with Pfizer is an important step in expanding access to trusted medicine information across Europe, and the beginning of understanding how French HCPs search.”

Aqid Iqbal, Europe and Canada Medical Information Operations Manager at Pfizer, explained: “Expanding access to Pfizer Medical Information through VIDAL is an important step in our Medical Information strategy of easing access and expanding reach.

“We are proud that Pfizer is the first manufacturer to make Scientific Response Documents available through this new service on VIDAL.”

Ferran Portella, Managing Director of VIDAL Group’s Medical Knowledge Solutions division, commented: “VIDAL’s role is to provide French healthcare professionals with accurate and reliable information on medicines.

“SRD Search extends what they can find on vidal.fr with approved, in-depth responses from manufacturers, accessible 24/7 whenever they need to make a prescription decision.”

### Related Stocks

- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [Pfizer Signs Licensing Deal With Starna Therapeutics for Autoimmune Disease Treatments](https://longbridge.com/en/news/305966590.md)
- [Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies](https://longbridge.com/en/news/306119677.md)
- [Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund](https://longbridge.com/en/news/305354338.md)
- [Pfizer, Innovent GLP-1 drugs added to China national insurance for diabetes](https://longbridge.com/en/news/305535476.md)
- [Blackstone Bankrolls Pfizer’s Weight Loss Drug Trials for Slice of Future Sales](https://longbridge.com/en/news/305334238.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**